Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02901301

Recruitment Status : Unknown

Verified April 2021 by Hyun Cheol Chung, Yonsei University.
Recruitment status was: Active, not recruiting

First Posted : September 15, 2016

Last Update Posted : April 6, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Hyun Cheol Chung, Yonsei University

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Unknown
Actual Primary Completion Date :	October 31, 2020
Estimated Study Completion Date :	October 2021

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	May 27, 2022	March 6, 2023
2	March 6, 2023	December 13, 2023

To Top